Effects of liraglutide on cardiovascular outcomes in patients with type 2 diabetes mellitus with or without history of myocardial infarction or stroke: Post hoc analysis from the leader trial

Circulation

Volumn 138, Issue 25, 2018, Pages 2884-2894

  Verma, Subodh ^b   Poulter, Neil R ^d   Bhatt, Deepak L ^e   Bain, Stephen C ^f   Buse, John B ^g   Leiter, Lawrence A ^c   Nauck, Michael A ^h   Pratley, Richard E ⁱ   Zinman, Bernard ^j   Ørsted, David D ^k   Fries, Tea Monk ^k   Rasmussen, Søren ^k   Marso, Steven P ^a,l  

^a Research Medical Center Brookside Campus   (United States)

^b Divisions of Cardiac Surgery   (United States)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f SWANSEA UNIVERSITY   (United Kingdom)

^g UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^h ST JOSEF HOSPITAL   (Germany)

ⁱ FLORIDA HOSPITAL   (United States)

^j MOUNT SINAI HOSPITAL   (Canada)

^k NOVO NORDISK A S   (Denmark)

^l Kansas City Heart Rhythm Institute at Hospital Corporation of America   (United States)

more..

Author keywords

Cardiovascular system; Diabetes mellitus, type 2; Glucagon like peptide 1; Liraglutide; Randomized controlled trial as topic

Indexed keywords

GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLYCOSYLATED HEMOGLOBIN; LIRAGLUTIDE; PLACEBO; ANTIDIABETIC AGENT;

ADULT; ANKLE BRACHIAL INDEX; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAROTID ARTERY OBSTRUCTION; CEREBRAL REVASCULARIZATION; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; ESTIMATED GLOMERULAR FILTRATION RATE; GASTROINTESTINAL SYMPTOM; HEALTH CARE QUALITY; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HOSPITALIZATION; HUMAN; HYPERTENSION; INCIDENCE; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MICROALBUMINURIA; MIDDLE AGED; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POST HOC ANALYSIS; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; SYSTOLIC BLOOD PRESSURE; UNSTABLE ANGINA PECTORIS; AGED; CANADA; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; PROPORTIONAL HAZARDS MODEL; RISK; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

AGED; CANADA; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; LIRAGLUTIDE; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROPORTIONAL HAZARDS MODELS; RISK; STROKE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 85058870723     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.118.034516     Document Type: Article

References (21)

1. Cavender MA, Steg PG, Smith SC Jr, Eagle K, Ohman EM, Goto S, Kuder J, Im K, Wilson PW, Bhatt DL; REACH Registry Investigators. Impact of diabetes mellitus on hospitalization for heart failure, cardiovascular events, and death: outcomes at 4 years from the Reduction of Atherothrombosis for Continued Health (REACH) registry. Circulation. 2015;132:923-931. doi: 10.1161/CIRCULATIONAHA.114.014796
2. Centers for Disease Control and Prevention. National diabetes statistics report. 2014. https://www.cdc.gov/diabetes/pdfs/data/2014-reportestimates-of-diabetes-and-its-burden-in-the-united-states.pdf. Accessed January 18, 2017.
3. Emerging Risk Factors Collaboration, Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, Ingelsson E, Lawlor DA, Selvin E, Stampfer M, Stehouwer CD, Lewington S, Pennells L, Thompson A, Sattar N, White IR, Ray KK, Danesh J. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375:2215-2222. doi: 10.1016/S0140-6736(10)60484-9
4. Bhatt DL, Bonaca MP, Bansilal S, Angiolillo DJ, Cohen M, Storey RF, Im K, Murphy SA, Held P, Braunwald E, Sabatine MS, Steg PG. Reduction in ischemic events with ticagrelor in diabetic patients with prior myocardial infarction in PEGASUS-TIMI 54. J Am Coll Cardiol. 2016;67:2732-2740. doi: 10.1016/j.jacc.2016.03.529
5. Bhatt DL. Antiplatelet therapy following myocardial infarction in patients with diabetes. JAMA. 2012;308:921-922. doi: 10.1001/2012.jama.11467
6. Hussain MA, Al-Omran M, Mamdani M. Efficacy of a guideline-recommended risk-reduction program to improve cardiovascular and limb outcomes in patients with peripheral arterial disease. J Vasc Surg. 2016;64:535. doi: 10.1016/j.jvs.2016.06.055
7. Burrows NR, Li Y, Gregg EW, Geiss LS. Declining rates of hospitalization for selected cardiovascular disease conditions among adults aged ≥35 years with diagnosed diabetes, U.S., 1998-2014. Diabetes Care. 2018;41:293-302. doi: 10.2337/dc17-1259
8. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016a;375:311-322. doi: 10.1056/NEJMoa1603827
9. Bhatt DL, Eagle KA, Ohman EM, Hirsch AT, Goto S, Mahoney EM, Wilson PW, Alberts MJ, D'Agostino R, Liau CS, Mas JL, Röther J, Smith SC Jr, Salette G, Contant CF, Massaro JM, Steg PG; REACH Registry Investigators. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA. 2010;304:1350-1357. doi: 10.1001/jama.2010.1322
10. Marso SP, Poulter NR, Nissen SE, Nauck MA, Zinman B, Daniels GH, Pocock S, Steinberg WM, Bergenstal RM, Mann JF, Ravn LS, Frandsen KB, Moses AC, Buse JB. Design of the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial. Am Heart J. 2013;166:823-830.e5. doi: 10.1016/j.ahj.2013.07.012
11. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496-509. doi: 10.2307/2670170.
12. Altman DG, Andersen PK. Calculating the number needed to treat for trials where the outcome is time to an event. BMJ. 1999;319:1492-1495.
13. Verma S, Bhatt DL, Bain SC, Buse JB, Mann JFE, Marso SP, Nauck MA, Poulter NR, Pratley RE, Zinman B, Michelsen MM, Monk Fries T, Rasmussen S, Leiter LA; LEADER Publication Committee on behalf of the LEADER Trial Investigators. Effect of liraglutide on cardiovascular events in patients with type 2 diabetes mellitus and polyvascular disease: results of the LEADER Trial. Circulation. 2018;137:2179-2183. doi: 10.1161/CIRCULATIONAHA.118.033898
14. Udell JA, Bonaca MP, Collet JP, Lincoff AM, Kereiakes DJ, Costa F, Lee CW, Mauri L, Valgimigli M, Park SJ, Montalescot G, Sabatine MS, Braunwald E, Bhatt DL. Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. Eur Heart J. 2016;37:390-399. doi: 10.1093/eurheartj/ehv443
15. Palmerini T, Benedetto U, Bacchi-Reggiani L, Della Riva D, Biondi-Zoccai G, Feres F, Abizaid A, Hong MK, Kim BK, Jang Y, Kim HS, Park KW, Genereux P, Bhatt DL, Orlandi C, De Servi S, Petrou M, Rapezzi C, Stone GW. Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and bayesian network meta-analysis of randomised trials. Lancet. 2015;385:2371-2382. doi: 10.1016/S0140-6736(15)60263-X
16. Verma S, Goodman SG, Mehta SR, Latter DA, Ruel M, Gupta M, Yanagawa B, Al-Omran M, Gupta N, Teoh H, Friedrich JO. Should dual antiplatelet therapy be used in patients following coronary artery bypass surgery? A meta-analysis of randomized controlled trials. BMC Surg. 2015;15:112. doi: 10.1186/s12893-015-0096-z
17. Sabatine MS, De Ferrari GM, Giugliano RP, Huber K, Lewis BS, Ferreira J, Kuder JF, Murphy SA, Wiviott SD, Kurtz C, Honarpour N, Keech AC, Sever PS, Pedersen TR. Clinical benefit of evolocumab by severity and extent of coronary artery disease: an analysis from FOURIER. Circulation. 2018;138:756-766. doi: 10.1161/CIRCULATIONAH.
18. Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan JC, Choi J, Gustavson SM, Iqbal N, Maggioni AP, Marso SP, Öhman P, Pagidipati NJ, Poulter N, Ramachandran A, Zinman B, Hernandez AF; EXSCEL Study Group. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377:1228-1239. doi: 10.1056/NEJMoa1612917.
19. Mahaffey KW, Neal B, Perkovic V, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Fabbrini E, Sun T, Li Q, Desai M, Matthews DR; CANVAS Program Collaborative Group. Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program (Canagliflozin Cardiovascular Assessment Study). Circulation. 2018;137:323-334. doi: 10.1161/CIRCULATIONAHA.117.032038
20. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsbøll T; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834-1844. doi: 10.1056/NEJMoa1607141
21. Nauck MA, Meier JJ, Cavender MA, Abd El Aziz M, Drucker DJ. Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Circulation. 2017;136:849-870. doi: 10.1161/CIRCULATIONAHA.117.028136